Lack of consideration of sex and gender in COVID-19 clinical studies

Titelaufnahme

Titel
Lack of consideration of sex and gender in COVID-19 clinical studies
Verfasser
Brady, Emer ; Nielsen, Mathias Wullum ; Andersen, Jens Peter ; Oertelt-Prigione, Sabine
Enthalten in
Nature Communications, Jg. 12 H. 1
Erschienen
2021
Sprache
Englisch
Dokumenttyp
Aufsatz in einer Zeitschrift
URN
urn:nbn:de:0070-pub-29570485
DOI
10.1038/s41467-021-24265-8

Zugriffsbeschränkung

Links

Dateien

Klassifikation

Abstract

Sex and gender differences impact the incidence of SARS-CoV-2 infection and COVID-19 mortality. Furthermore, sex differences influence the frequency and severity of pharmacological side effects. A large number of clinical trials to develop new therapeutic approaches and vaccines for COVID-19 are ongoing. We investigated the inclusion of sex and/or gender in COVID-19 studies on ClinicalTrials.gov, collecting data for the period January 1, 2020 to January 26, 2021. Here, we show that of the 4,420 registered SARS-CoV-2/COVID-19 studies, 935 (21.2%) address sex/gender solely in the context of recruitment, 237 (5.4%) plan sex-matched or representative samples or emphasized sex/gender reporting, and only 178 (4%) explicitly report a plan to include sex/gender as an analytical variable. Just eight (17.8%) of the 45 COVID-19 related clinical trials published in scientific journals until December 15, 2020 report sex-disaggregated results or subgroup analyses. Sex and gender have been associated with differences in SARS-CoV-2 incidence and clinical outcomes and therefore warrant consideration in study designs. Here, the authors assess registered and published clinical COVID-19 studies and find that sex-disaggregated analyses are infrequently presented or planned.

Inhalt

Statistik

Lizenz-/Rechtehinweis